Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Zmień bibliotekę

Wyszukujesz frazę ""Therapeutic innovation & regulatory science [Ther Innov Regul Sci] NLMUID: 101597411"" wg kryterium: JN


Tytuł :
Common Commentary on Paediatric Oncology Drug Development Published: Another Step in Optimising Global Regulatory Coordination of Paediatric Development Plans.
Autorzy :
Karres D; Paediatric Medicines Office, Human Medicines Division, Scientific Evidence Generation Department, European Medicines Agency (EMA), Amsterdam, The Netherlands. .
Reaman G; Oncology Center of Excellence, Office of the Commissioner, Office of Oncologic Diseases, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, USA.
Ligas F; Paediatric Medicines Office, Human Medicines Division, Scientific Evidence Generation Department, European Medicines Agency (EMA), Amsterdam, The Netherlands.
Lesa G; Paediatric Medicines Office, Human Medicines Division, Scientific Evidence Generation Department, European Medicines Agency (EMA), Amsterdam, The Netherlands.
McCune S; Office of Pediatric Therapeutics, Office of the Commissioner, US Food and Drug Administration (FDA), Silver Spring, USA.
Malli S; Office of Pediatric Therapeutics, Office of the Commissioner, US Food and Drug Administration (FDA), Silver Spring, USA.
Bax R; Paediatric Medicines Office, Human Medicines Division, Scientific Evidence Generation Department, European Medicines Agency (EMA), Amsterdam, The Netherlands.
Temeck J; Office of Pediatric Therapeutics, Office of the Commissioner, US Food and Drug Administration (FDA), Silver Spring, USA.
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep 08. Date of Electronic Publication: 2021 Sep 08.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Adverse Events in the Digital Age: Finding the Sharpest Tool in the Box.
Autorzy :
Di Giovanni R; Chief Medical Office and Patient Safety, Global Drug Development, Novartis Pharma AG, Basel, Switzerland. .
Cochrane A; Chief Medical Office and Patient Safety, Global Drug Development, Novartis Pharma AG, Basel, Switzerland.
Lewis DJ; Chief Medical Office and Patient Safety, Global Drug Development, Novartis Pharma GmbH, Oeflinger Strasse 44, 79664, Wehr, Germany.; Department of Pharmacy, Pharmacology and Postgraduate Medicine, University of Hertfordshire, Hatfield, AL10 9AB, Herts, UK.
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep 07. Date of Electronic Publication: 2021 Sep 07.
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Tytuł :
Oncology Products in the European Union: An Analysis of Regulatory Approvals with a CHMP Oral Explanation.
Autorzy :
Oger A; MSD Europe Inc, Clos du Lynx 5, 1200, Brussels, Belgium. .
Torqui A; MSD, Oss, The Netherlands.
Kester R; Merck & Co., Inc., Rahway, NJ, USA.
Wissink S; MSD, Oss, The Netherlands.
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep; Vol. 55 (5), pp. 1036-1044. Date of Electronic Publication: 2021 May 26.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Approval*
European Union ; Humans
Czasopismo naukowe
Tytuł :
Biennial Analysis of Medication Guide Length and Estimated Readability for New Molecular Entity Drugs, 2011-2017.
Autorzy :
Jones PR; Center for Drug Evaluation and Research, Office of Medical Policy, Office of Medical Policy Initiatives, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, WO Bldg 51, Third Floor, Silver Spring, MD, 20993, USA. .
Walther EJ; Center for Drug Evaluation and Research, Office of Medical Policy, Office of Medical Policy Initiatives, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, WO Bldg 51, Third Floor, Silver Spring, MD, 20993, USA.
Nguyen A; Center for Drug Evaluation and Research, Office of Medical Policy, Office of Medical Policy Initiatives, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, WO Bldg 51, Third Floor, Silver Spring, MD, 20993, USA.
Santiago J; Center for Drug Evaluation and Research, Office of Medical Policy, Office of Medical Policy Initiatives, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, WO Bldg 51, Third Floor, Silver Spring, MD, 20993, USA.
Pearsall BM; Center for Drug Evaluation and Research, Office of Medical Policy, Office of Medical Policy Initiatives, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, WO Bldg 51, Third Floor, Silver Spring, MD, 20993, USA.
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep; Vol. 55 (5), pp. 918-925. Date of Electronic Publication: 2021 May 10.
Typ publikacji :
Journal Article
MeSH Terms :
Health Literacy*
Pharmaceutical Preparations*
Comprehension ; Educational Status ; Humans ; Reading
Czasopismo naukowe
Tytuł :
Correction to: Characterizing Pain Points in Clinical Data Management and Assessing the Impact of Mid-Study Updates.
Autorzy :
Harper B; Clinical Performance Partners, Aurora, IL, USA.
Smith Z; Tufts CSDD, 75 Kneeland Street- Floor 11, Boston, MA, USA. .
Snowdon J; IBM Watson Health, Cambridge, MA, USA.
DiCicco R; IBM Watson Health, Cambridge, MA, USA.
Hekmat R; IBM Watson Health, Cambridge, MA, USA.
Van Willis; IBM Watson Health, Cambridge, MA, USA.
Weeraratne D; IBM Watson Health, Cambridge, MA, USA.
Getz K; Tufts CSDD, 75 Kneeland Street- Floor 11, Boston, MA, USA.
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep; Vol. 55 (5), pp. 1013.
Typ publikacji :
Published Erratum
Tytuł :
Characterizing Pain Points in Clinical Data Management and Assessing the Impact of Mid-Study Updates.
Autorzy :
Harper B; Clinical Performance Partners, Aurora, IL, USA.
Smith Z; Tufts CSDD, 75 Kneeland Street- Floor 11, Boston, MA, USA. .
Snowdon J; IBM Watson Health, Cambridge, MA, USA.
DiCicco R; IBM Watson Health, Cambridge, MA, USA.
Hekmat R; IBM Watson Health, Cambridge, MA, USA.
Van Willis; IBM Watson Health, Cambridge, MA, USA.
Weeraratne D; IBM Watson Health, Cambridge, MA, USA.
Getz K; Tufts CSDD, 75 Kneeland Street- Floor 11, Boston, MA, USA.
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep; Vol. 55 (5), pp. 1006-1012. Date of Electronic Publication: 2021 May 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Data Management*
Drug Development*
Humans ; Pain ; Surveys and Questionnaires
Czasopismo naukowe
Tytuł :
Proof of Concept: Drug Selection? Or Dose Selection? Thoughts on Multiplicity Issues.
Autorzy :
Li QH; Global Biometrics and Data Sciences, Bristol Myers Squibb - Global Biopharmaceutical Company, NewYork, USA.
Deng Q; Biostatistics and Data Sciences, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, USA.
Ting N; Biostatistics and Data Sciences, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, USA. .
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep; Vol. 55 (5), pp. 1001-1005. Date of Electronic Publication: 2021 May 24.
Typ publikacji :
Journal Article
MeSH Terms :
Pharmaceutical Preparations*
Humans
Czasopismo naukowe
Tytuł :
Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic.
Autorzy :
Qu Y; Eli Lilly and Company, Indianapolis, IN, 46285, USA. .; Department of Data and Analytics, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA. .
Lipkovich I; Eli Lilly and Company, Indianapolis, IN, 46285, USA.
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep; Vol. 55 (5), pp. 984-988. Date of Electronic Publication: 2021 May 13.
Typ publikacji :
Journal Article
MeSH Terms :
COVID-19*
Pandemics*
Data Interpretation, Statistical ; Humans ; Research Design ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
Sustaining Meaningful Patient Engagement Across the Lifecycle of Medicines: A Roadmap for Action.
Autorzy :
Cavaller-Bellaubi M; EURORDIS-Rare Diseases Europe, Paris, France.
Faulkner SD; Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Rd, Oxford, OX2 6GG, UK.
Teixeira B; European AIDS Treatment Group (EATG), Düsseldorf, Germany.
Boudes M; European Patients' Forum (EPF), Chaussée d'Etterbeek, Brussels, Belgium.
Molero E; Teamit Research S.L., Barcelona, Spain.
Brooke N; The Synergist, Brussels, Belgium.
McKeaveney L; Novartis International AG, Basel, Switzerland.
Southerton J; Pfizer Inc, San Diego, CA, USA.
Vicente MJ; Aragón Health Sciences Institute, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain.
Bertelsen N; Health Technology Assessment International (HTAi)-Patient and Citizen Involvement Interest Group, Berlin, Germany.
García-Burgos J; European Medicines Agency (EMA), Amsterdam, The Netherlands.
Pirard V; Sanofi-Genzyme, Brussels, Belgium.
Reid K; European Federation of Pharmaceutical Industries and Associations (EFPIA), Brussels, Belgium.
Ferrer E; EURORDIS-Rare Diseases Europe, Paris, France. .
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep; Vol. 55 (5), pp. 936-953. Date of Electronic Publication: 2021 May 10.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Patient Participation*
Technology Assessment, Biomedical*
Europe ; Humans
Czasopismo naukowe
Tytuł :
Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial.
Autorzy :
Rosenberg L; The Leukemia & Lymphoma Society, Leukemia & Lymphoma Society (National Office), 3 International Drive, Suite 200, Rye Brook, NY, 10573, USA.
Levaux H; Protocol First, Salt Lake City, USA.
Levine RL; Memorial Sloan Kettering Cancer Center, New York, USA.
Shah A; Protocol First, Salt Lake City, USA.
Denmark J; myClin, Yardley, USA.
Hereema N; The Ohio State University James Cancer Center, Columbus, USA.
Owen M; Syneos Health, Morrisville, USA.
Kalk S; Syneos Health, Morrisville, USA.
Kenny N; Syneos Health, Morrisville, USA.
Vinson G; Syneos Health, Morrisville, USA.
Vergilio JA; Foundation Medicine, Cambridge, USA.
Mims A; The Ohio State University James Cancer Center, Columbus, USA.
Borate U; The Ohio State University James Cancer Center, Columbus, USA.
Blum W; Emory University Winship Cancer Institute, Atlanta, Georgia.
Stein E; Memorial Sloan Kettering Cancer Center, New York, USA.
Gana TJ; The Leukemia & Lymphoma Society, Leukemia & Lymphoma Society (National Office), 3 International Drive, Suite 200, Rye Brook, NY, 10573, USA.
Stefanos M; The Ohio State University James Cancer Center, Columbus, USA.
Yocum A; The Leukemia & Lymphoma Society, Leukemia & Lymphoma Society (National Office), 3 International Drive, Suite 200, Rye Brook, NY, 10573, USA.
Marcus S; The Leukemia & Lymphoma Society, Leukemia & Lymphoma Society (National Office), 3 International Drive, Suite 200, Rye Brook, NY, 10573, USA.
Shoben A; The Ohio State University James Cancer Center, Columbus, USA.
Druker B; The Ohio State University James Cancer Center, Columbus, USA.
Byrd J; The Ohio State University James Cancer Center, Columbus, USA.
Burd A; The Leukemia & Lymphoma Society, Leukemia & Lymphoma Society (National Office), 3 International Drive, Suite 200, Rye Brook, NY, 10573, USA. .
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep; Vol. 55 (5), pp. 926-935. Date of Electronic Publication: 2021 May 16.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Leukemia, Myeloid, Acute*/drug therapy
Humans ; Technology
Czasopismo naukowe
Tytuł :
Government Pharmaceutical Development to Address High Prices: Challenges Ahead.
Autorzy :
Darrow JJ; Program On Regulation, Therapeutics, And Law (PORTAL), Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont St., Suite 3030, Boston, MA, 02120, USA. .; Department of Law and Taxation, Bentley University, Waltham, MA, 02452, USA. .
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep; Vol. 55 (5), pp. 1103-1105. Date of Electronic Publication: 2021 Jul 14.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Costs*
Drug Industry*
Costs and Cost Analysis ; Drug Development ; Government ; Humans
Czasopismo naukowe
Tytuł :
The Role of Regulatory Sciences from the Perspective of the Cuban Medicines Regulatory Agency: The Impact of COVID-19 in Promoting Innovation, Cooperation and Scientific Thinking.
Autorzy :
Romeu B; Secretary Executive Office of Innovation, Center for State Control of Medicines and Medical Devices (CECMED), Havana, Cuba. .
Rodríguez Y; Former Deputy Director, Center for State Control of Medicines and Medical Devices (CECMED), Havana, Cuba.
Bendiner S; WESSX. Inc, Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep; Vol. 55 (5), pp. 1014-1018. Date of Electronic Publication: 2021 May 03.
Typ publikacji :
Journal Article
MeSH Terms :
COVID-19*
Vaccines*
Government Agencies ; Humans ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
Factors Influencing Classifications of Safety Specifications in a Risk Management Plan for Antineoplastic Agents Approved in Japan: A Review and Descriptive Analysis.
Autorzy :
Ezaki A; Department of Regulatory Science of Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hirakawa A; Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Hanaoka H; Department of Regulatory Science of Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.; Division of Clinical Research Center, Chiba University Hospital, Chiba, Japan.
Uyama Y; Department of Regulatory Science of Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan. .; Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki, Chiyodaku, Tokyo, 100-0013, Japan. .; Graduate School of Medicine, Nagoya University, Nagoya, Japan. .
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep; Vol. 55 (5), pp. 1075-1081. Date of Electronic Publication: 2021 Jun 09.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Agents*
Risk Management*
Humans ; Japan ; Risk Assessment
Czasopismo naukowe
Tytuł :
Clinical Quality Considerations when Using Next-Generation Sequencing (NGS) in Clinical Drug Development.
Autorzy :
Ménard T; F. Hoffmann-La Roche AG, Basel, Switzerland. .
Barros A; Genentech Inc. - A Member of the Roche Group, South San Francisco, USA.
Ganter C; Genentech Inc. - A Member of the Roche Group, South San Francisco, USA.
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep; Vol. 55 (5), pp. 1066-1074. Date of Electronic Publication: 2021 May 27.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
High-Throughput Nucleotide Sequencing*
Precision Medicine*
Drug Development ; Humans
Czasopismo naukowe
Tytuł :
An FDA Analysis of Inspected Entities After Receiving Official Action Indicated Letters for Good Clinical Practice Violations.
Autorzy :
Jung M; Compliance Enforcement Branch, Division of Enforcement and Postmarketing Safety, Office of Scientific Investigations, Office of Compliance, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.
Swann RM; Compliance Enforcement Branch, Division of Enforcement and Postmarketing Safety, Office of Scientific Investigations, Office of Compliance, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.
Anantha MS; Compliance Enforcement Branch, Division of Enforcement and Postmarketing Safety, Office of Scientific Investigations, Office of Compliance, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.
Jamali F; Compliance Enforcement Branch, Division of Enforcement and Postmarketing Safety, Office of Scientific Investigations, Office of Compliance, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA. .
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep; Vol. 55 (5), pp. 907-917. Date of Electronic Publication: 2021 Jun 08.
Typ publikacji :
Journal Article
MeSH Terms :
Research Personnel*
Cross-Sectional Studies ; Humans ; United States ; United States Food and Drug Administration
Czasopismo naukowe
Tytuł :
The Use of External Controls in FDA Regulatory Decision Making.
Autorzy :
Jahanshahi M; BioMarin Pharmaceutical Inc, 105 Digital Drive, Novato, CA, 94949, USA. .
Gregg K; BioMarin Pharmaceutical Inc, 105 Digital Drive, Novato, CA, 94949, USA.
Davis G; BioMarin Pharmaceutical Inc, 105 Digital Drive, Novato, CA, 94949, USA.
Ndu A; BioMarin Pharmaceutical Inc, 105 Digital Drive, Novato, CA, 94949, USA.
Miller V; Forum for Collaborative Research, University of California School of Public Health, Washington, DC, 20036, USA.
Vockley J; School of Medicine, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA, 15224, USA.
Ollivier C; Aparito, Leiden Bioscience Park, BioPartner 3, 8 Galileiweg, 2333 BE, Leiden, The Netherlands.
Franolic T; BioMarin Pharmaceutical Inc, 105 Digital Drive, Novato, CA, 94949, USA.
Sakai S; Tempest Therapeutics, 7000 Shoreline Court, Suite 275, South San Francisco, CA, 94080, USA.
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep; Vol. 55 (5), pp. 1019-1035. Date of Electronic Publication: 2021 May 20.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Drug Approval*
Rare Diseases*
Decision Making ; Humans ; Retrospective Studies ; United States ; United States Food and Drug Administration
Czasopismo naukowe
Tytuł :
Patient Engagement Initiatives in Clinical Trials: Recent Trends and Implications.
Autorzy :
Sine S; Center for Information and Study on Clinical Research Participation, One Liberty Square, Suite 1100, Boston, MA, 02109, USA.; Tufts University School of Medicine, Boston, MA, USA.
de Bruin A; Center for Information and Study on Clinical Research Participation, One Liberty Square, Suite 1100, Boston, MA, 02109, USA. .
Getz K; Center for Information and Study on Clinical Research Participation, One Liberty Square, Suite 1100, Boston, MA, 02109, USA.; Tufts University School of Medicine, Boston, MA, USA.
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep; Vol. 55 (5), pp. 1059-1065. Date of Electronic Publication: 2021 Jun 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Patient Participation*
Humans ; Surveys and Questionnaires
Czasopismo naukowe
Tytuł :
Prescribing Information for Antihypertensive Medications Lacks Dose-Specific Blood Pressure Response.
Autorzy :
Vyas R; School of Pharmacy, University of Maryland Baltimore, 20 N. Pine Street, Baltimore, MD, 21201, USA. .
Cooke CE; School of Pharmacy, University of Maryland Baltimore, 20 N. Pine Street, Baltimore, MD, 21201, USA.
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep; Vol. 55 (5), pp. 1101-1102. Date of Electronic Publication: 2021 Jun 14.
Typ publikacji :
Letter
MeSH Terms :
Antihypertensive Agents*/pharmacology
Antihypertensive Agents*/therapeutic use
Blood Pressure ; Humans
Opinia redakcyjna
Tytuł :
Dissolution Profiles of Generic Products in Dissolution Media Defined by Japanese Guidelines for Bioequivalence Studies.
Autorzy :
Kajiwara E; MSD K.K., KITANOMARU SQUARE, 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo, 102-8667, Japan. .; Department of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan. .
Kamizato H; Department of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan.
Shikano M; Department of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan.
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep; Vol. 55 (5), pp. 1096-1100. Date of Electronic Publication: 2021 Jun 07.
Typ publikacji :
Journal Article
MeSH Terms :
Biopharmaceutics*
Drugs, Generic*
Humans ; Japan ; Solubility ; Therapeutic Equivalency
Czasopismo naukowe
Tytuł :
Evaluating Metrics Applied to the Medical Science Liaison (MSL) Role: A Survey-Based Study of Canadian MSL Leaders.
Autorzy :
Saleem M; Hoffmann-La Roche Ltd., Mississauga, ON, Canada.
Cesario L; Hoffmann-La Roche Ltd., Mississauga, ON, Canada.
Wilcox L; Pfizer Canada Inc., Kirkland, QC, Canada.
Haynes M; Janssen Inc., Toronto, ON, Canada.
Collin S; AbbVie Corp., Saint-Laurent, QC, Canada.
Langlois P; AstraZeneca Canada Inc., Mississauga, ON, Canada.
Kenyon S; Placencia Holdings Ltd., Hamilton, ON, Canada. .
Chilelli A; Astellas Pharma Canada Inc., Markham, ON, Canada.
Pokaż więcej
Źródło :
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2021 Sep; Vol. 55 (5), pp. 954-965. Date of Electronic Publication: 2021 May 04.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Benchmarking*
Leadership*
Canada ; Health Personnel ; Humans ; Surveys and Questionnaires
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies